Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients requiring intravenous feeding when oral or enteral nutrition is not possible, insufficient, or contraindicated.,Adjunct to other nutritional support in conditions such as gastrointestinal tract obstruction, malabsorption, preoperative bowel rest, or severe catabolic states.
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable as a single entity; components have variable half-lives: dextrose ~1-2h, amino acids ~1-3h for distribution, electrolytes vary. No terminal half-life defined.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Amino acids are metabolized via transamination and deamination pathways; dextrose is metabolized via glycolysis and the citric acid cycle; electrolytes are not metabolized but are utilized in physiological processes.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Excretion depends on amino acid and electrolyte composition; nitrogen waste is eliminated renally as urea. Calcium and magnesium are primarily renally excreted; potassium is mostly renally eliminated. Dextrose is metabolized to CO2 and water. In renal impairment, accumulation may occur.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Low for amino acids and electrolytes; calcium ~40% bound to albumin, magnesium ~30% bound, potassium not protein-bound.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not defined as a composite; amino acids distribute into total body water (0.5-0.6 L/kg), calcium distributes into extracellular fluid (~0.2 L/kg), potassium intracellularly (~4 L/kg).
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
100% (intravenous administration).
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
Contraindicated in severe renal failure (e GFR < 30 m L/min/1.73 m²) without renal replacement therapy; if used, reduce dose by 50% for moderate impairment (e GFR 30-59 m L/min/1.73 m²) and monitor electrolytes.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in Child-Pugh class B (reduce amino acid dose by 50-75%); no adjustment for Child-Pugh class A.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Dose based on body weight: Amino acids: 1-3 g/kg/day; Dextrose: 5-20 g/kg/day. Initiate at lower end and increase gradually. Typical infusion rate: 1-2 m L/kg/hour, titrate to blood glucose and metabolic tolerance. Not recommended for neonates without risk-benefit assessment.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
No specific dose adjustment, but use with caution due to potential age-related decline in renal function. Monitor fluid balance and renal function; start at lower doses (e.g., 500 m L/day) and adjust based on tolerance and clinical response.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
Not applicable. CLINIMIX E does not carry an FDA black box warning.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Risk of infection due to catheter-related bloodstream infections; strict aseptic technique required.,Metabolic complications including hyperglycemia, hypoglycemia, electrolyte imbalances, and acid-base disturbances.,Hepatic and renal function monitoring required; adjust infusion rates accordingly.,Aluminum toxicity risk in patients with renal impairment; prolonged use may lead to bone disease.,Do not administer simultaneously with blood products through the same infusion line.
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to any component of the solution.,Severe electrolyte disturbances or metabolic acidosis.,Anuria or severe renal impairment (unless dialyzed adequately).,Hepatic coma or severe hepatic insufficiency.,Uncorrected hyperglycemia or hyperosmolar coma.
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
None; this is an intravenous solution providing nutrition. Do not consume oral nutrients without clinical guidance as it may interfere with nutritional balance.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components at physiological concentrations. However, calcium administration in the third trimester may be associated with neonatal hypocalcemia if maternal hypercalcemia occurs. No specific fetal risks are identified for the first two trimesters when used as indicated for parenteral nutrition.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Safety in breastfeeding is not established. Components excrete into milk in low amounts; no specific M/P ratio available. Parenteral nutrition use in lactating women should be with caution. Monitor infant for electrolyte imbalance.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Pregnancy may increase fluid and electrolyte requirements. Glucose monitoring is essential as gestational diabetes may develop. Calcium dosing may need adjustment to avoid hypercalcemia. No specific dose changes for amino acids; follow standard parenteral nutrition guidelines. Adjust infusion rate based on clinical status and avoid iatrogenic hyperglycemia.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
This is a premixed parenteral nutrition solution containing amino acids, dextrose, electrolytes, and calcium. Do not add other medications or supplements without compatibility verification. Monitor serum electrolytes, glucose, and calcium levels regularly. Use inline filter; do not administer if precipitate is present. Contains sulfite-free formulation; safe for sulfite-sensitive patients.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This medication is given through a vein; do not stop or adjust the infusion rate on your own.,Report any signs of infection at the IV site (redness, swelling, pain) or allergic reactions (rash, difficulty breathing).,This solution provides complete nutrition; do not eat or drink without your doctor's approval.,Notify your doctor if you experience nausea, vomiting, headache, or unusual tiredness.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose for intravenous infusion. It supplies essential and non-essential amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is: Administer intravenously. Dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 500-2000 m L per day, infused at a rate not exceeding 2-3 m L/kg/hour (or 2 mg/kg/min of amino acids), equivalent to 1-1.5 g/kg/day of amino acids and 3-7 g/kg/day of dextrose.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/5 contains amino acids, dextrose, and electrolytes, including calcium. No teratogenic effects have been reported in animal or human studies with standard components. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.